These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 22115635)
1. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Berzofsky JA Vaccine; 2012 Jun; 30(29):4323-7. PubMed ID: 22115635 [TBL] [Abstract][Full Text] [Related]
2. Strategies to use immune modulators in therapeutic vaccines against cancer. Berzofsky JA; Terabe M; Wood LV Semin Oncol; 2012 Jun; 39(3):348-57. PubMed ID: 22595057 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904 [TBL] [Abstract][Full Text] [Related]
4. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258 [TBL] [Abstract][Full Text] [Related]
5. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Assudani D; Cho HI; DeVito N; Bradley N; Celis E Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170 [TBL] [Abstract][Full Text] [Related]
6. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8 Zahm CD; Colluru VT; McNeel DG Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215 [TBL] [Abstract][Full Text] [Related]
8. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686 [TBL] [Abstract][Full Text] [Related]
10. Broadly Protective CD8 Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S J Virol; 2021 May; 95(12):. PubMed ID: 33827939 [TBL] [Abstract][Full Text] [Related]
11. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM Expert Rev Vaccines; 2011 Nov; 10(11):1569-83. PubMed ID: 22043956 [TBL] [Abstract][Full Text] [Related]
12. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Salucci V; Mennuni C; Calvaruso F; Cerino R; Neuner P; Ciliberto G; La Monica N; Scarselli E Scand J Immunol; 2006 Jan; 63(1):35-41. PubMed ID: 16398699 [TBL] [Abstract][Full Text] [Related]
14. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Yang Z; Wang L; Wang H; Shang X; Niu W; Li J; Wu Y Mol Immunol; 2008 Mar; 45(6):1674-81. PubMed ID: 18035418 [TBL] [Abstract][Full Text] [Related]